• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

MedMen Expands Market Share in California with Acquisition of Long Beach Retailer

Share:

June 10, 2019

MedMen Enterprises Inc. announced that it has signed a definitive agreement to acquire a 100% stake in MattnJeremy, Inc. LLC d/b/a One Love Beach Club. The acquisition further enhances MedMen’s industry-leading California footprint, adding a premier location strategically located between its Santa Ana and LAX locations. One Love is currently on a run-rate of approximately $6 million in unaudited gross revenue with an unaudited EBITDA margin of approximately 29%.1

“We’re excited to welcome Long Beach to the MedMen family and continue our growth in the most important cannabis market in the world,” said Adam Bierman, MedMen CEO.

One Love was established in 2009 and is located at 2767 E Broadway in Long Beach, a few blocks away from the beach between Downtown and Belmont Shore. Located 20 miles south of Los Angeles, Long Beach is Southern California’s third largest city, behind Los Angeles and San Diego, with just under a half-million residents. The coastal city offers oceanfront hotels, attractions, events, shopping, recreational activities, art and culture, restaurants and nightly entertainment. The Long Beach Convention & Visitors Bureau estimated that more than 7.9 million visitors came to the city in 2018 to attend its attractions and events.

“It has been an honor serving the Long Beach community over the past ten years,” said the Abrams Family, owner and operators of One Love. “We look forward to MedMen continuing to provide our community with high quality cannabis.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Transaction Details

As consideration for the transaction, the Company will pay $13 million, of which $10 million will be satisfied in Class B Subordinate Voting shares (“Shares”), $1 million in cash at closing and $2 million in deferred cash. The transaction is subject to regulatory approvals by local and state authorities and other customary closing conditions. The Company expects the transaction to close within 45 days.

1. Based on unaudited financials provided by One Love.

Date: June 10, 2019

Source: Financial Post

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference CallProvention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
  • Nanox and Usard Expand Their Radiology Diagnostic Partnership; Sera Prognostics and Anthem Launch a Neonatal Outcomes Study; and More Digital Health DealsNanox and Usard Expand Their Radiology Diagnostic Partnership; Sera Prognostics and Anthem Launch a Neonatal Outcomes Study; and More Digital Health Deals
  • GoodRx Looks to Consumer Education with Purchase of Health Video Company HealthiNationGoodRx Looks to Consumer Education with Purchase of Health Video Company HealthiNation
  • Premier Health Enters into Definitive Agreement to Acquire Two Operating Pharmacies in Metro VancouverPremier Health Enters into Definitive Agreement to Acquire Two Operating Pharmacies in Metro Vancouver
  • Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI PharmaInfinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
  • Abcam : Enters Cell Editing Market Through Acquisition of EdiGene’s Knock-out Cell Lines and Lysates PortfolioAbcam : Enters Cell Editing Market Through Acquisition of EdiGene’s Knock-out Cell Lines and Lysates Portfolio
  • Agragene’s Knock-Out™ Product Utilizes Live Sterile Male Insects as a Form of Insect Pest ControlAgragene’s Knock-Out™ Product Utilizes Live Sterile Male Insects as a Form of Insect Pest Control
  • Natural Health Farm Holdings, Inc. Continues Global Expansion with Agreement to Acquire USA Based Natural Health Farm, Inc

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications